12:07 PM EST, 01/30/2025 (MT Newswires) -- Jupiter Neurosciences ( JUNS ) said Thursday that it has entered into a partnership with Zina Biopharmaceuticals for an upcoming phase 2a clinical trial to evaluate Jupiter's Jotrol resveratrol-based platform in Parkinson's disease.

Zina will assist with trial design, regulatory strategy, and trial site selection, according to Jupiter.

The study has a primary objective of evaluating the safety and tolerability of Jotrol, with secondary endpoints to assess the drug's pharmacokinetics and pharmacodynamics, Jupiter said.

Jupiter also said it is exploring partnerships to look into Jotrol's potential for treating other neuroinflammatory and metabolic disorders, including Alzheimer's disease.

Shares of Jupiter were down more than 5% in recent trading.

Price: 1.15, Change: -0.07, Percent Change: -5.74